Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 17320177)

Published in Mol Immunol on February 22, 2007


Krisztina K Timár1, Sami Junnikkala, Attila Dallos, Hanna Jarva, Zahurul A Bhuiyan, Seppo Meri, Jan D Bos, Syed S Asghar

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands.

Articles by these authors

Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57

Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation (2006) 3.44

New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96

Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med (2006) 2.65

The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med (2008) 2.34

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J Immunol (2002) 2.06

Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol (2007) 2.00

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. Cardiovasc Res (2003) 1.89

Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol (2011) 1.89

Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol (2002) 1.87

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Tumor necrosis factor alpha enhances influenza A virus-induced expression of antiviral cytokines by activating RIG-I gene expression. J Virol (2006) 1.75

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J (2006) 1.72

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol (2009) 1.70

Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol (2003) 1.68

IFN-alpha enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol (2005) 1.67

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc Natl Acad Sci U S A (2011) 1.58

Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. Heart Rhythm (2006) 1.57

Increased DNA damage sensitivity of Cornelia de Lange syndrome cells: evidence for impaired recombinational repair. Hum Mol Genet (2007) 1.56

Complement resistance mechanisms of streptococci. Mol Immunol (2003) 1.56

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies. Heart Rhythm (2008) 1.56

Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem (2003) 1.55

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm (2011) 1.46

Complement regulator-acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J Immunol (2005) 1.42

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol (2005) 1.40

Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol (2005) 1.38

Yersinia enterocolitica serum resistance proteins YadA and ail bind the complement regulator C4b-binding protein. PLoS Pathog (2008) 1.36

Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33

Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J Immunol (2002) 1.32

Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27

Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol (2008) 1.23

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Regulation of complement activation at the C3-level by serum resistant leptospires. Microb Pathog (2005) 1.21

Lysine-dependent multipoint binding of the Borrelia burgdorferi virulence factor outer surface protein E to the C terminus of factor H. J Immunol (2004) 1.20

Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A (2005) 1.20

HERG channel (dys)function revealed by dynamic action potential clamp technique. Biophys J (2004) 1.20

Clinical isolates of Streptococcus pneumoniae bind the complement inhibitor C4b-binding protein in a PspC allele-dependent fashion. J Immunol (2009) 1.18

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagy-mediated proteolysis in human retinal pigment epithelial cells. J Cell Mol Med (2008) 1.14

Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine (2011) 1.12

Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery (2006) 1.11

Comparison of surface recognition and C3b binding properties of mouse and human complement factor H. Mol Immunol (2005) 1.10

Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun (2008) 1.10

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol (2003) 1.08

Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol (2004) 1.07

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm (2012) 1.06

The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement. Infect Immun (2010) 1.05

Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun (2010) 1.05

Microbial complement inhibitors as vaccines. Vaccine (2008) 1.05

Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives. Circ Arrhythm Electrophysiol (2012) 1.05

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun (2009) 1.04

Overview of psoriasis. Dermatol Ther (2004) 1.04

Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population. Mol Vis (2006) 1.04

Role of sequence variations in the human ether-a-go-go-related gene (HERG, KCNH2) in the Brugada syndrome. Cardiovasc Res (2005) 1.03

Complement C3 contributes to ethanol-induced liver steatosis in mice. Ann Med (2006) 1.03

Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS One (2008) 1.03

Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology (2012) 1.02

Activation of complement components and reduced regulator expression in alcohol-induced liver injury in the rat. Clin Immunol (2002) 1.00

Expression of complement factor H binding immunoevasion proteins in Borrelia garinii isolated from patients with neuroborreliosis. Eur J Immunol (2005) 1.00

Functional mapping of YadA- and Ail-mediated binding of human factor H to Yersinia enterocolitica serotype O:3. Infect Immun (2008) 0.99

The surface protease PgtE of Salmonella enterica affects complement activity by proteolytically cleaving C3b, C4b and C5. FEBS Lett (2007) 0.99

Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol (2007) 0.99

Complement factor H as a marker for detection of bladder cancer. Clin Chem (2005) 0.98

Factor H binding as a complement evasion mechanism for an anaerobic pathogen, Fusobacterium necrophorum. J Immunol (2008) 0.97

Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest (2009) 0.97

The group B streptococcal beta and pneumococcal Hic proteins are structurally related immune evasion molecules that bind the complement inhibitor factor H in an analogous fashion. J Immunol (2004) 0.97

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Binding of the complement inhibitor C4b-binding protein to Lyme disease Borreliae. Mol Immunol (2009) 0.97

Interdomain contact regions and angles between adjacent short consensus repeat domains. J Mol Biol (2004) 0.97

Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. Hum Mol Genet (2009) 0.96